伊立替康
医学
贝伐单抗
内科学
中性粒细胞减少症
养生
临床终点
结直肠癌
临床研究阶段
肿瘤科
不利影响
化疗方案
耐火材料(行星科学)
外科
胃肠病学
化疗
癌症
临床试验
天体生物学
物理
作者
Baoqi Li,Wenwei Yang,Na Liu,Deying Bi,Tingting Yang,Guifu Wu,Yongkun Sun
标识
DOI:10.1038/s41416-024-02885-3
摘要
PURPOSE: To explore the efficacy and safety of the combination of irinotecan, trifluridine/tipiracil (TAS-102), and bevacizumab in a later-line setting for metastatic colorectal cancer (mCRC) patients. PATIENTS AND METHODS: This was a single-center, phase II trial. The mCRC patients who are refractory to standard first-line and second-line treatment are eligible. Patients who previously received irinotecan while progressing during maintenance therapy are also eligible. The primary endpoint was the objective response rate (ORR). RESULTS: Between August 1, 2022, and September 30, 2023, 35 patients were enrolled, and 31 of them were evaluable for efficacy. The ORR was 25.8% (8/31), and the disease control rate (DCR) was 93.5% (29/31). As of April 30, 2024, the median progression-free survival (PFS) was 9.2 months (95% CI 6.285-12.115), whereas the median overall survival (OS) was not reached with the 1-year OS rate of 73.5%. The most common grade 3/4 treatment-related adverse events were neutropenia (34.3%), anemia (17.1%), and thrombocytopenia (8.6%). CONCLUSION: Irinotecan, TAS-102 plus bevacizumab regimen preliminarily demonstrated promising efficacy with tolerable toxicity for mCRC patients as later-line treatment. This regimen warrants further exploration in refractory mCRC patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI